Clinical trials: Coronavirus (SARS-CoV)
Covid19, SARS-CoV Infection
Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine
Randomized, Blind, Placebo-controlled Phase- I Study and Randomized, Open Phase Phase-II Study of QazCoVac-P - COVID-19 Subunit Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder
- Conditions
- Covid19, SARS-CoV Infection, Vaccine Adverse Reaction
- Trial name
- NCT04930003
- Testing
- QazCoVac-P -COVID-19 Subunit Vaccine
- Where
- Kazakhstan
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Research Institute for Biological Safety Problems
COVID-19, SARS-CoV 2
Tannin Specific Natural Extract for COVID-19 Infection
There is an urgent need to evaluate interventions that could be effective against the infection with SARS-CoV 2. Tannins based wood extracts are an inexpensive and safe product with protective effect in both bacterial and viral…
- Conditions
- COVID-19, SARS-CoV 2, Coronavirus Infection
- Trial name
- TanCOVID (NCT04403646)
- Testing
- ARBOX
- Where
- Argentina
- Volunteers
- 124 people
- Sponsor
- Hospital de Clinicas José de San Martín
SARS-CoV Infection, Covid19
Use of Hypochlorous Acid as Prophylaxis in Health Personnel at High Risk of Infection by SARS-CoV 2 (COVID19)
The pandemic caused by SARS-CoV-2 is a global emergency present in 6 continents including 66 countries, incurring a shortage of effective and safe therapeutic alternatives that can contribute to reducing the risk of…
- Conditions
- SARS-CoV Infection, Covid19, Infection Viral
- Trial name
- NCT04684550
- Testing
- Stabilized hypochlorous acid
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hospital Universitario San Ignacio
Covid19, SARS-CoV Infection
Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department
The main objective of this cohort is to characterize COVID-19 patients hospitalized in infectious disease department. The collection of clinical and biological data from start of hospitalization to long-term follow up will…
- Trial name
- NCT04779021
- Testing
- Hospitalisation for SARS-COV2 infection
- Where
- 2 sites in France
- Volunteers
- 1,300 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
SARS-CoV Infection, Covid19
Can the Electronic Nose Smell COVID-19 Antibodies?
Corona Virus Disease (COVID-19), spread worldwide and has become an emergency of major international concern. In March 2020, the WHO declared the COVID-19 outbreak a global pandemic.
- Trial name
- NCT04475575
- Testing
- Aeonose
- Where
- Netherlands
- Volunteers
- 222 people
- Sponsor
- Maastricht University Medical Center
Covid19
Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients
Severe ill Patients will be enrolled in the study (n=310) after duly filled consent forms. Recipients will be divided into 2 group, each group contain 155 patients to compare Safety and efficacy of patients in Clinical Trial…
- Trial name
- NCT04891172
- Testing
- Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)
- Where
- Pakistan
- Volunteers
- 310 people
- Sponsor
- Dow University of Health Sciences
SARS
Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study
This is a multi-center, randomized, double-blinded, placebo-controlled, outpatient study. Recombinant deltaTM S Protein Severe Acute Respiratory Syndrome (SARS) Vaccine With and Without Aluminum Hydroxide Adjuvant (Provided…
- Trial name
- NCT01376765
- Testing
- Aluminum hydroxide adjuvant (Alhydrogel®), Recombinant S protein SARS vaccine
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV Infection
Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19
Clinical research focused to evaluate the effect as coadyuvant of a combination of L. plantarum and P. acidilactici in adults positive for SARS-CoV-2 with mild clinical COVID-19 symptoms.
- Trial name
- NCT04517422
- Testing
- Probiotics
- Where
- Mexico
- Volunteers
- 300 people
- Sponsor
- AB Biotics, SA
Healthy Participants
Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
The purpose of this study is to estimate the effect PF-07321332/Ritonavir and Ritonavir on Midazolam (a cytochrome P450 [CYP]3A4 substrate) in Healthy Adult Participants.
- Trial name
- NCT05032950
- Testing
- Midazolam, PF-07321332/ritonavir + Midazolam, Ritonavir + Midazolam
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS CoV 2 Infection, Pneumonia
SP16 as a Therapeutic for COVID-19 Induced ARDS
This randomized, double-blind, placebo-controlled, Phase 1b study evaluates the safety and tolerability, and effects on cytokine and acute phase reactants of SP16, an anti-inflammatory drug, in patients with pneumonia due to…
- Trial name
- NCT05135624
- Testing
- SP16 (6mg), SP16 (12 mg)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Serpin Pharma, LLC
Rheumatic Diseases, SARS-CoV Infection
Longitudinal Follow-up of Patients With Chronic Inflammatory Rheumatisms (CIRs) Vaccinated Against COVID-19 Compared to Patients Refusing Vaccination
To date, studies on SARS-CoV2and vaccines have been mostly from the general population not exposed to immunosuppressants. The efficacy and safety of COVID-19 vaccines need to be evaluated in these populations.
- Conditions
- Rheumatic Diseases, SARS-CoV Infection, COVID-19
- Trial name
- COVID-RIC3 (NCT04832022)
- Testing
- Biological samples
- Where
- 13 sites in France
- Volunteers
- 397 people
- Sponsor
- University Hospital, Montpellier
Coronavirus (SARS-CoV)
SARS Coronavirus Vaccine (SARS-CoV)
Severe acute respiratory syndrome (SARS) is a viral illness that affects the respiratory (breathing) system. The purpose of this study is to evaluate the safety and protective (immune) responses to different doses of a SARS…
- Trial name
- NCT00533741
- Testing
- Aluminum hydroxide, SARS-CoV
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Post Acute Sequelae of SARS CoV 2 Infection, Obstructive Sleep Apnea
Predictors of Post-COVID-19 Clinical and Cognitive Consequences
The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients.
- Trial name
- SCLC (NCT06291870)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Covid19, Coronavirus
Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
The investigators aim to carry out a retrospective observational study, analysing lung ultrasound images from patients who have presented to A\&E for routine diagnostic purposes (ruling out cardiogenic pulmonary oedema, Pulmonary…
- Conditions
- Covid19, Coronavirus, Corona Virus Infection, SARS-CoV Infection
- Trial name
- NCT05065827
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Coronavirus Infection, Severe Acute Respiratory Syndrome
COVID-19 Seroprevalence Study in French Guiana
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Syndrome, SARS-CoV Infection, Covid19
- Trial name
- EPI-COVID-POP (NCT04490850)
- Testing
- Blood sample
- Where
- 5 sites in French Guiana
- Volunteers
- 3,541 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
SARS-CoV 2
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
- Trial name
- CSSC-004 (NCT04373460)
- Testing
- SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
- Where
- 29 sites in United States
- Volunteers
- 1,225 people
- Sponsor
- Johns Hopkins University
Covid19, Corona Virus Infection
T Cells Response to SARS COV 2 Peptides
The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral…
- Trial name
- NCT04573348
- Testing
- Savicell's ImmunoBiopsy™
- Where
- Israel
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Savicell Diagnostics Ltd
SARS-CoV 2, COVID-19
Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19
Prospective study for clinical performance evaluation of COVID-19 diagnostic tests: detection of anti-SARS-CoV-2 antibodies by RDTs or ELISA (manual or automated), rapid diagnostic tests based on antigen detection, molecular or…
- Trial name
- ERap-COV (NCT04405492)
- Testing
- Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling., Capillary and salivary sampling
- Volunteers
- 1,210 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Ozone Plasma on Lung Function and Inflammatory Parameters in Pulmonary Sequelae Associated With Coronavirus 19 Infection
The risk for the development of complications from COVID-19 occurs mainly in patients over 65 years of age, with obesity, arterial hypertension, chronic lung diseases and immunosuppression states.
- Trial name
- NCT05089305
- Testing
- Ozone plasma
- Where
- 2 sites in Mexico
- Volunteers
- 35 people
- Sponsor
- Centro Universitario de Ciencias de la Salud, Mexico
Covid-19, SARS-CoV Infection
RT-PCR Database Analysis for COVID-19 Infections and Re-infection
The SARS-Cov2 pandemic remains associated with many concerns. One of the them is the real frequency of likely re-infection and subsequently the level of protection conferred by the acquired immunity following primary-infection.
- Trial name
- ReCOV (NCT04653844)
- Where
- France
- Volunteers
- 7,000,000 people
- Sponsor
- University Hospital, Montpellier